In MM, characterized by an accumulation of malignant plasma cells in bone marrow, the only therapeutic radiopharmaceutical that has entered clinical application so far is the small cyclic pentapeptide pentixafor and its analogue pentixather (binding to the chemokine receptor CXCR4) introduced earlier. This evidence concerns the gene CXCR4 and Miyoshi myopathy.